44 Stocks Moving In Friday’s Mid-Day Session
Gainers
Guardforce AI Co., Limited (NASDAQ: GFAI) shares jumped 42% to $3.5350 after the company said it has engaged Int'l. Investor Relations Co., MZ Group, to lead strategic investor relations and financial communications program.
Why Are CareDx Shares Slumping Despite Q3 Earnings Beat?
CareDx Inc (NASDAQ:CDNA) reported Q3 revenues rose 42% Y/Y to $75.6 million, beating the consensus of $74.05 million.…
Raymond James Maintains Strong Buy on CareDx, Lowers Price Target to $90
Raymond James analyst Andrew Cooper maintains CareDx (NASDAQ:CDNA) with a Strong Buy and lowers the price target from $108 to $90.
CareDx: Q3 Earnings Insights
CareDx (NASDAQ:CDNA) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:00 PM.
Here's what investors need to know about the announcement.
CareDx Q3 EPS $0.07 Beats $0.01 Estimate, Sales $75.59M Beat $74.05M Estimate
CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.01 by 600 percent. This is a 30 percent decrease over earnings of $0.10 per share from the same period
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
CareDx And Eledon Pharmaceuticals Announce Collaborative Research Agreement
CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and